Relmada Therapeutics, Inc. RLMD Share-Based Payment - Nonvested Awards (Number)

Share-Based Payment - Nonvested Awards (Number) at other companies

IDT CorporationIDT

18K-87.8%

Flagstar Bank FLG

2.8M-59.3%

Orange County BancorpOBT

0—

Encore Capital GroupECPG

871.1K+43.4%

KopinKOPN

6.6M+4.5%

American Battery Technology CompanyABAT

13.6M+73.6%

Operating income-$19.5M-6.8%

Net income-$19.1M-8.5%

EPS (diluted)-$0.22+62.1%

Cash & equivalents$9.8M+750%

Total debt$104.1M-40.4%

Total equity$218.7M+875%

Total assets$235.4M+750%

Operating cash flow-$15.1M+16.6%

Market cap$677.17M+2,907%

Return on equity-48.8%-20.0pp

Debt / equity0.9×0.0×

Current ratio18.3×+13.0×

Reported directly by Relmada Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber.

The official record: Relmada Therapeutics, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and compare it to peers, right in your chat.

What is Relmada Therapeutics, Inc.'s share-based payment - nonvested awards (number)?: Relmada Therapeutics, Inc. (RLMD) reported share-based payment - nonvested awards (number) of 8M in Q1 2026.